Rodrigo Valderrama, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1144240656
Payments from drug & device makers
Across 1,295 payments — averaging $46.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$36K
- Novo Nordisk$3K
- Lilly USA, LLC$3K
- Medtronic$3K
- Abbott$2K
- AstraZeneca$2K
- plus $13K from 50 others
What the payments were for
- Consulting fees$3,9917%
- Speaking & faculty fees$25,48742%
- Travel & lodging$6,09610%
- Food & beverage$25,23741%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yorvipath$14,297
- Minimed 670G System$696
- MINIMED 780G$548
- iLet Bionic Pancreas$440
- Saxenda$242
- Kerendia$242
- FreeStyle Libre$139
- NATPARA (PARATHYROID HORMONE)$125
- InPen$120
- QSYMIA$120
- ISTURISA$118
- Livalo$116
- Wegovy$107
- Ozempic$101
How this compares
$60,844 in reported general payments places this provider in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 528 | $588,618 |
| OzempicSemaglutide | 429 | $578,533 |
| Tresiba Flextouch U-200Insulin Degludec | 106 | $235,423 |
| KorlymMifepristone | 11 | $231,415 |
| JardianceEmpagliflozin | 189 | $171,939 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 101 | $136,807 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 127 | $110,004 |
| FarxigaDapagliflozin Propanediol | 97 | $99,332 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 81 | $98,562 |
| TrulicityDulaglutide | 80 | $94,187 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 60 | $93,837 |
| Tresiba Flextouch U-100Insulin Degludec | 109 | $84,942 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 105 | $77,043 |
| RybelsusSemaglutide | 20 | $32,938 |
| SynthroidLevothyroxine Sodium | 308 | $28,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $2,833 | $723,128674 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $3,254 | $626,087493 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $520 | $317,608307 claims |
| Corcept TherapeuticsKorlym | $1,342 | $231,41511 claims |
| AstraZenecaFarxiga | $1,510 | $99,33297 claims |
| MerckJanumet Xr, Januvia | $156 | $88,054120 claims |
| AbbVieSynthroid | $706 | $28,508308 claims |
| Johnson & JohnsonInvokana | $201 | $13,37419 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $130 | $10,515801 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- William GarveyBirmingham$3.8M
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Amy WarrinerBirmingham$182K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Tom VaughanBirmingham$68K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Ananda BasuBirmingham$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.